Clinical trials: Placebo Effect
Sickle Cell Disease
Voxelotor Neurocognitive Function Study
This is a Phase 3b, randomized, double-blind, placebo-controlled, multicenter study to assess the treatment effect of voxelotor on neurocognitive function as assessed by the National Institute of Health (NIH) Toolbox Cognition…
- Trial name
- NCT05228834
- Testing
- Voxelotor Only Product in Oral Dose Form
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Endometriosis
Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic…
- Trial name
- QLARITY (NCT03749109)
- Testing
- Quinagolide 1080 µg
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 67 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Obstructive Pulmonary Disease
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- BLAZE (NCT01490125)
- Testing
- QVA149, Tiotropium, Salbutamol/albuterol
- Where
- 43 sites in Belgium, Canada and 3 more
- Volunteers
- 247 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Stem Cell Transplant Complications
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
This study evaluates the use of 2% CHG washcloths in an outpatient setting for adults after hematopoietic stem cell transplant in prevention of central line associated blood stream infections.
- Trial name
- NCT03030989
- Testing
- Chlorhexidine Gluconate 2% Wipe
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Musculoskeletal Diseases
Phase 1 Study of ACE-083 in Healthy Subjects
This study will evaluate the safety and tolerability of single and multiple doses of ACE-083 as a local injection into selected skeletal muscles of healthy subjects.
- Trial name
- NCT02257489
- Testing
- ACE-083
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Spasticity, Multiple Sclerosis
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study is to evaluate the maintenance of effect after long-term treatment with Sativex® in subjects with symptoms of spasticity due to Multiple Sclerosis (MS) who have been receiving long-term benefit from…
- Trial name
- NCT00702468
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Jazz Pharmaceuticals
Alzheimer's Disease
Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
- Trial name
- DISCOVER (NCT02925650)
- Testing
- Posiphen
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Annovis Bio Inc.
Alzheimer's Disease
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).
- Trial name
- DHA (NCT00440050)
- Testing
- DHA (Docosahexaenoic Acid)
- Where
- 51 sites in United States
- Volunteers
- 402 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Parkinson's Disease
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
This study involves Parkinson's disease (PD). Symptoms include slow movement, tremor, and muscle rigidity. Current medications for the treatment of PD do not improve gait and balance difficulties in individuals with PD.
- Trial name
- NCT01521117
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Oregon Health and Science University
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Medication Adherence
Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
The current study will use the double-blind balanced placebo design to examine differences between expectancies versus the pharmacological effects of varenicline medication administered for two weeks to cigarette smokers.
- Trial name
- NCT03538808
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
SRD-Part: To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses (SRD) of BI 1569912 BA/FE-Part: To investigate (a) the relative bioavailability (BA) of BI 1569912 and (b) the…
- Trial name
- NCT04445090
- Testing
- BI 1569912
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.
- Trial name
- NCT01128179
- Testing
- Lanthanum carbonate
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Shire
Anxiety, Preoperative Anxiety
Comparing the Effect of Melatonin, Diazepam, and Placebo on Decreasing the Level of Anxiety Preoperatively
The goal of this clinical trial is to compare the effect of melatonin, diazepam, and placebo on the level of anxiety in patients undergoing surgery.
- Trial name
- NCT06103188
- Testing
- Diazepam, Melatonin
- Where
- Jordan
- Volunteers
- 87 people
- Sponsor
- University of Jordan
Atopic Dermatitis
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo.
- Trial name
- NCT05121480
- Testing
- EDP1815
- Where
- 59 sites in United States, Australia and 4 more
- Volunteers
- 421 people
- Sponsor
- Evelo Biosciences, Inc.
Healthy
Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
Investigation of safety, tolerability, pharmacokinetics and pharmacodynamics of single rising doses of BI 705564 and of the food effect on BI 705564 in healthy male subjects
- Trial name
- NCT03123185
- Testing
- BI 705564 (Test), BI 705564 (Reference)
- Where
- Germany
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
The purpose of the study was to evaluate the efficacy and safety of LMF237 50/250 mg and 50/500 mg bid in Japanese patients with T2DM inadequately controlled with vildagliptin monotherapy.
- Trial name
- CLMF237A1303 (NCT01811485)
- Testing
- LMF237 50/250 mg, LMF237 50/500 mg
- Where
- 30 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Use Disorder
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, 2 fixed sequences, multiple dose study in healthy male and/or female recreational opioid users.
- Trial name
- NCT05587998
- Testing
- Morphine, AZD4041
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Erectile Dysfunction
Effect of Tadalafil Once a Day in Men With Erectile Dysfunction
The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors.
- Trial name
- NCT00836693
- Testing
- tadalafil
- Where
- 21 sites in Germany, Greece and 3 more
- Volunteers
- 217 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.